Book a Meeting

Fc Engineered Anti-Human CD38 Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ17] (CAT#: BioBet-C017ZP) Datasheet

Target
CD38
Isotype
Whole Human Antibody
Description
CDC-enhanced Daratumumab is a Fc-modified anti-CD38 therapeutic biobetter. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Daratumumab, the Fc region of Daratumumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Multiple Myeloma (MM)
Classification
Therapeutic antibody; biobetter
Patent
Not Available
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop CDC-enhanced Daratumumab. For commercial partners interested in our CDC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD38
Full Name
platelet derived growth factor receptor alpha
Background
This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies suggest that this gene plays a role in organ development, wound healing, and tumor progression. Mutations in this gene have been associated with idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers.
Alternative Names
Platelet Derived Growth Factor Receptor Alpha; Platelet-Derived Growth Factor Receptor, Alpha Polypeptide; Alpha-Type Platelet-Derived Growth Factor Receptor; Platelet-Derived Growth Factor Receptor 2; CD140 Antigen-Like Family Member A; CD140a Antigen; PDGF-R-Alpha; EC 2.7.10.1; PDGFR-2;
Gene ID
5156
UniProt ID
P16234
Trade name
Darzalex
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB09331
CAS number
945721-28-8
Antibody Isotype
Human IgG1
Description
Daratumumab is an anticancer drug that specifically targets CD38. It received accelerated FDA approval in November 2016 for a breakthrough therapeutic drug for multiple myeloma.
Indication
Multiple Myeloma (MM)
Synonyms
Not Available
UNII
4Z63YK6E0E

Daratumumab is an immunoglobulin G1κ monoclonal antibody that specifically targets the CD38 antigen. CD38 is a transmembrane glycoprotein with many functions and is highly expressed in hematological malignancies, including multiple myeloma tumors. CD38 can regulate receptor-mediated adhesion, signaling, and cyclase and hydrolase activity. Daratumumab inhibits tumor cell growth and induces broad-spectrum apoptosis by binding to CD38 in a variety of mechanisms: Fc-mediated cross-linking, complement-dependent cytotoxicity, antibody-dependent cytotoxicity, and immune-dependent cell phagocytosis Lead tumor cell lysis.

Multiple Myeloma (MM)

Related Products

Fc Engineered Anti-Human CD38 Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ130] (CAT#: Biobet-C130ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany